About Aurion Biotech
Aurion Biotech is a company based in Seattle (United States) founded in 2021 was acquired by Alcon in March 2025. It operates as a HealthTech. Aurion Biotech has raised $120 million across 1 funding round from investors including Alcon, KKR and Falcon-Vision. Aurion Biotech offers products and services including Cell Therapy for Corneal Endothelial Disease. Aurion Biotech operates in a competitive market with competitors including ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aurion Biotech Japan, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aurion Biotech
Aurion Biotech offers a comprehensive portfolio of products and services, including Cell Therapy for Corneal Endothelial Disease. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cell therapy is developed for corneal endothelial diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Aurion Biotech
Aurion Biotech has successfully raised a total of $120M through 1 strategic funding round. The most recent funding activity was a Series C round of $120 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series C — $120.0M
-
First Round
First Round
(12 Apr 2022)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2022 | Amount | Series C - Aurion Biotech | Valuation | Deerfield |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aurion Biotech
Aurion Biotech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Alcon, KKR and Falcon-Vision. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Petrichor is engaged in supporting healthcare innovation through investments.
|
Founded Year | Domain | Location | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aurion Biotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aurion Biotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aurion Biotech Comparisons
Competitors of Aurion Biotech
Aurion Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
|
| domain | founded_year | HQ Location |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
|
| domain | founded_year | HQ Location |
Cell-based therapies are developed for intractable neurological diseases.
|
|
| domain | founded_year | HQ Location |
Developer of stem cells to regrow damaged bones
|
|
| domain | founded_year | HQ Location |
Cell therapies for cancer and serious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Tissue engineering company utilizing a proprietary stem technology to treat degenerative disc disease.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aurion Biotech
Frequently Asked Questions about Aurion Biotech
When was Aurion Biotech founded?
Aurion Biotech was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Aurion Biotech located?
Aurion Biotech is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of Aurion Biotech?
Greg Kunst is the current CEO of Aurion Biotech.
Is Aurion Biotech a funded company?
Aurion Biotech is a funded company, having raised a total of $120M across 1 funding round to date. The company's 1st funding round was a Series C of $120M, raised on Apr 12, 2022.
What does Aurion Biotech do?
Aurion Biotech is engaged in the development of innovative therapies aimed at restoring vision. The company operates as a clinical-stage biotech entity with a primary focus on ocular diseases, particularly corneal endothelial dystrophies. A patented cell therapy treatment is being developed as their first candidate to address these conditions. Their work spans across the healthcare sector, emphasizing accessible and effective solutions for patients worldwide.
Who are the top competitors of Aurion Biotech?
Aurion Biotech's top competitors include EpiBone, Neurona Therapeutics and Gamida Cell.
What products or services does Aurion Biotech offer?
Aurion Biotech offers Cell Therapy for Corneal Endothelial Disease.
Who are Aurion Biotech's investors?
Aurion Biotech has 7 investors. Key investors include Alcon, KKR, Falcon-Vision, Deerfield, and Petrichor.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.